These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32586750)

  • 1. Author response to Wang et al. Blood neurofilament light chain in Parkinson's disease: A biological marker for prediction of cognitive impairment?
    Sampedro F; Kulisevsky J
    Parkinsonism Relat Disord; 2020 Aug; 77():159. PubMed ID: 32586750
    [No Abstract]   [Full Text] [Related]  

  • 2. Blood neurofilament light chain in Parkinson's disease: A biological marker for prediction of cognitive impairment?
    Wang H; Wang W; Shi H; Han L
    Parkinsonism Relat Disord; 2020 Aug; 77():157-158. PubMed ID: 32563681
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease.
    Ma LZ; Zhang C; Wang H; Ma YH; Shen XN; Wang J; Tan L; Dong Q; Yu JT
    J Parkinsons Dis; 2021; 11(3):1117-1127. PubMed ID: 33935105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
    Aamodt WW; Waligorska T; Shen J; Tropea TF; Siderowf A; Weintraub D; Grossman M; Irwin D; Wolk DA; Xie SX; Trojanowski JQ; Shaw LM; Chen-Plotkin AS
    Mov Disord; 2021 Dec; 36(12):2945-2950. PubMed ID: 34480363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Plasma and Neuroimaging Biomarkers Associated with Motor and Cognition Severity in Parkinson's Disease.
    Chen CH; Lee BC; Lin CH
    J Parkinsons Dis; 2020; 10(1):77-88. PubMed ID: 31868681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease.
    Sampedro F; Pérez-González R; Martínez-Horta S; Marín-Lahoz J; Pagonabarraga J; Kulisevsky J
    Parkinsonism Relat Disord; 2020 May; 74():43-49. PubMed ID: 32334380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease.
    Zhu Y; Yang B; Wang F; Liu B; Li K; Yin K; Yin WF; Zhou C; Tian S; Ren H; Pang A; Yang X
    J Neuroimmunol; 2021 Sep; 358():577662. PubMed ID: 34311152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories.
    Lerche S; Wurster I; Röben B; Zimmermann M; Machetanz G; Wiethoff S; Dehnert M; Rietschel L; Riebenbauer B; Deuschle C; Stransky E; Lieplt-Scarfone I; Gasser T; Brockmann K
    Mov Disord; 2020 Jul; 35(7):1138-1144. PubMed ID: 32445500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum level of YWHAG as a diagnostic marker of cognitive impairment in Parkinson's disease patients.
    Peng Y; Zhu L; Bai Q; Wang L; Li Q
    Acta Neurol Belg; 2024 Jun; 124(3):879-885. PubMed ID: 38286872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD).
    Buhmann C; Lezius S; Pötter-Nerger M; Gerloff C; Kuhle J; Choe CU
    Mov Disord; 2022 Feb; 37(2):435-436. PubMed ID: 35040209
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to: "Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD)".
    Aamodt WW; Chen-Plotkin AS
    Mov Disord; 2022 Feb; 37(2):436-437. PubMed ID: 35150470
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma Neurofilament Light Concentration Is Associated with Diffusion-Tensor MRI-Based Measures of Neurodegeneration in Early Parkinson's Disease.
    Welton T; Tan YJ; Saffari SE; Ng SYE; Chia NSY; Yong ACW; Choi X; Heng DL; Shih YC; Hartono S; Lee W; Xu Z; Tay KY; Au WL; Tan EK; Chan LL; Ng ASL; Tan LCS
    J Parkinsons Dis; 2022; 12(7):2135-2146. PubMed ID: 36057833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma neurofilament light chain levels are associated with depressive and anxiety symptoms in Parkinson's disease.
    Yin W; Zhu Y; Yang B; Wang F; Yin K; Zhou C; Ren H; Yang X
    Neurol Sci; 2022 Apr; 43(4):2839-2843. PubMed ID: 35088243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood neurofilament light chain in Parkinson's disease.
    Buhmann C; Magnus T; Choe CU
    J Neural Transm (Vienna); 2023 Jun; 130(6):755-762. PubMed ID: 37067597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease: Long-Term Observation and Implications of Clinical Subtypes.
    Ygland Rödström E; Mattsson-Carlgren N; Janelidze S; Hansson O; Puschmann A
    J Parkinsons Dis; 2022; 12(2):571-584. PubMed ID: 34806619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder.
    Requena-Ocaña N; Araos P; Serrano-Castro PJ; Flores-López M; García-Marchena N; Oliver-Martos B; Ruiz JJ; Gavito A; Pavón FJ; Serrano A; Mayoral F; Suarez J; Fonseca FR
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroimaging correlates of cognitive impairment and dementia in Parkinson's disease.
    Mak E; Su L; Williams GB; O'Brien JT
    Parkinsonism Relat Disord; 2015 Aug; 21(8):862-70. PubMed ID: 26004683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease.
    Wilke C; Dos Santos MCT; Schulte C; Deuschle C; Scheller D; Verbelen M; Brockmann K; von Thaler AK; Sünkel U; Roeben B; Bujac S; Metzger FG; Maetzler W; da Costa AN; Synofzik M; Berg D
    Mov Disord; 2020 Jul; 35(7):1233-1238. PubMed ID: 32338403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.
    Goldman JG; Aggarwal NT; Schroeder CD
    Neurodegener Dis Manag; 2015 Oct; 5(5):425-43. PubMed ID: 26517759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.